In a 2018 study, Terali assessed the seven commercially available neonicotinoids using docking calculations, revealing different binding modes with AChE and BChE, and suggesting them to be potential compounds to treat cholinergic and non-cholinergic AD pathogenesis [133]. The gene discussed is ACHE; the disease is Alzheimer disease.